Table 1.
Clinical characteristics | n | % | p | ||
---|---|---|---|---|---|
Breast malignant tumor | Gender | Male | 0 | 0% | — |
Female | 26 | 100% | |||
Age | ≤50 | 12 | 46% | 0.31 | |
>50 | 14 | 54% | |||
Pathology | Intraductal carcinoma | 26 | 100% | — | |
Histological grade | I | 3 | 12% | — | |
II | 16 | 62% | |||
III | 4 | 15% | |||
ER | Negative | 13 | 50% | 0.885 | |
Positive | 13 | 50% | |||
PR | Negative | 13 | 50% | 0.66 | |
Positive | 13 | 50% | |||
HER2 | Negative | 7 | 27% | 0.3 | |
Positive | 19 | 73% | |||
Lymph node | Negative | 13 | 50% | 0.02∗ | |
Positive | 13 | 50% | |||
| |||||
Breast benign tumor | Gender | Male | 3 | 30% | — |
Female | 7 | 70% | |||
Age | <50 | 3 | 30% | — | |
≥50 | 7 | 70% | |||
Pathology | Hyperplasia | 4 | 40% | — | |
Intraductal papilloma | 1 | 10% | |||
Cystic disease and hyperplasia | 3 | 30% | |||
Fibroadenoma | 2 | 20% |
∗ p < 0.05 and this was considered statistically significant.